Compared side by side
Retatrutide vs cagrilintide: how they differ
The short answer
They act on different hormones: retatrutide activates three receptors, GLP-1, GIP and glucagon, while cagrilintide is a long-acting analogue of amylin, the fullness hormone the pancreas releases with insulin. Neither is approved; cagrilintide is the amylin half of Novo Nordisk’s CagriSema, and the crowd mostly runs it beside a GLP-1 drug such as retatrutide. Both are weekly shots, with half-lives of about 6 days for retatrutide and about a week for cagrilintide.
Side by side
| Compared | Retatrutide | Cagrilintide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | LY3437943 | Cagri, AM833, NNC0174-0833 |
| What it is | The first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice). | A long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot. |
| How it works | Triple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one. | Long-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema. |
| Commonly reported | Appetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet. | Feeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own. |
| Studied range | Research range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation. | Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~6 days (measured in early trials in people) | ~1 week (measured in people: 159–195 hours in a phase 1b trial) |
| Route | SubQ injection | SubQ injection |
| Typical run | Phase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration. | Trials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain | Nausea, constipation, diarrhea, injection-site reactions |
- Category
- RetatrutideMetabolic & GLP-1
- CagrilintideMetabolic & GLP-1
- Also known as
- RetatrutideLY3437943
- CagrilintideCagri, AM833, NNC0174-0833
- What it is
- RetatrutideThe first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice).
- CagrilintideA long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot.
- How it works
- RetatrutideTriple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one.
- CagrilintideLong-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema.
- Commonly reported
- RetatrutideAppetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet.
- CagrilintideFeeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own.
- Studied range
- RetatrutideResearch range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation.
- CagrilintideResearch range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.
- How often
- RetatrutideWeekly
- CagrilintideWeekly
- Half-life
- Retatrutide~6 days (measured in early trials in people)
- Cagrilintide~1 week (measured in people: 159–195 hours in a phase 1b trial)
- Route
- RetatrutideSubQ injection
- CagrilintideSubQ injection
- Typical run
- RetatrutidePhase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration.
- CagrilintideTrials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1.
- Evidence
- RetatrutideEstablished: clinical trials or FDA-approved use exists
- CagrilintideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- RetatrutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain
- CagrilintideNausea, constipation, diarrhea, injection-site reactions
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Retatrutide
- Day 1–28 · 2 mg Triple-agonist is kicking in
- Day 29–84 · 4 mg Dose-response steepens
- Day 60+ · 9 mg Watch for dysesthesia at higher doses
- Day 84+ This is a maintenance medication, not a course
- Day 85–168 · 8 mg Higher steps: strong satiety
- Day 169–336 No plateau yet at week 48
- Day 337–476 Phase 3 territory: the headline numbers
Cagrilintide
- Day 1–28 · 0.25 mg The 0.25 mg start
- Day 29–364 · 0.5 mg 0.5 mg, the second step
- Day 57–364 · 1 mg 1 mg, the middle step
- Day 85–364 · 1.7 mg 1.7 mg, the step before 2.4 mg
- Day 113+ · 2.4 mg 2.4 mg, the phase 3 dose
Together or one or the other
Retatrutide and cagrilintide are a common stack: cagrilintide lists retatrutide among its common stacks.
Animal · Cagrilintide
With retatrutide or tirzepatide: the crowd's stacks
Cagrilintide beside retatrutide or tirzepatide is a common crowd stack, on the same logic as CagriSema. No trial in people has tested these pairs; in obese rats, cagrilintide plus retatrutide lost more weight than either alone.
Questions people ask
How long do retatrutide and cagrilintide last?
The half-life of retatrutide is ~6 days (measured in early trials in people). The half-life of cagrilintide is ~1 week (measured in people: 159–195 hours in a phase 1b trial).
How often are retatrutide and cagrilintide taken?
Retatrutide: weekly. Route: SubQ injection. Cagrilintide: weekly. Route: SubQ injection.
How are retatrutide and cagrilintide dosed in research?
The research range for retatrutide is 1–12 mg, with a 2 mg starting dose. The research range for cagrilintide is 0.25–2.4 mg, with a 0.25 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of retatrutide and cagrilintide?
For retatrutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain. For cagrilintide: nausea, constipation, diarrhea, injection-site reactions.
Are retatrutide and cagrilintide taken together?
Retatrutide and cagrilintide are a common stack: cagrilintide lists retatrutide among its common stacks. Cagrilintide beside retatrutide or tirzepatide is a common crowd stack, on the same logic as CagriSema. No trial in people has tested these pairs; in obese rats, cagrilintide plus retatrutide lost more weight than either alone.